Author + information
- Received March 26, 2013
- Revision received May 22, 2013
- Accepted June 13, 2013
- Published online October 8, 2013.
- Wojciech Kosmala, MD, PhD∗,
- David J. Holland, PhD†,
- Aleksandra Rojek, MD∗,
- Leah Wright, BS‡,
- Monika Przewlocka-Kosmala, MD, PhD∗ and
- Thomas H. Marwick, MD, PhD‡∗ ()
- ∗Wroclaw Medical University, Wroclaw, Poland
- †University of Queensland, Brisbane, Australia
- ‡Menzies Research Institute Tasmania, Hobart, Australia
- ↵∗Reprint requests and correspondence:
Dr. Thomas H. Marwick, Menzies Research Institute Tasmania, 17 Liverpool Street, Hobart, T7000, Australia.
Objectives The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).
Background Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.
Methods Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial. Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.
Results The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004). Work load–corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group. Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = −0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.
Conclusions In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity. Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful. (Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received March 26, 2013.
- Revision received May 22, 2013.
- Accepted June 13, 2013.
- American College of Cardiology Foundation